21 February 2024
21 February 2024 07:00 GMT Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission AstraZeneca PLC (the Company) announced today that,…
21 February 2024 Production growth of 3% from focused investment in the health of our business; underlying EBITDA of $23.9 billion and full year ordinary…
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals…
19 February 2024
19 February 2024 Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial First EGFR inhibitor…
19 February 2024 B.P. Marsh & Partners Plc (“B.P. Marsh”, the “Company” or the “Group”) Trading Update The Directors of B.P. Marsh & Partners…
15 February 2024
GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the…
Half Year 2024 Exceptional Items Update BHP announces two items which will be recognised as exceptional items in BHP’s financial results for the half…
15 February 2024 Rockwood Strategic plc(“RKW” or the “Company”) Issue of Equity, TVR and Investment Manager Shareholding Issue of Equity and Total Voting Rights On 14…